Apricus Biosciences, Inc.???s (APRI) shares inched down by 1.6% over the last trading session following the company???s announcement that it has entered into an exclusive licensing agreement with Recordati for the commercialization of Vitaros in Spain, Russia, Turkey, Ireland and some other countries in Europe and Africa.